Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Hofman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Best Practice & Research. Clinical Haematology|June 11, 2011
Imaging in follicular NHLM S Hofman, R J Hicks
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 13, 2011
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectableT W Barber, M S Hofman, B N J Thomson, et al.
World Journal of Urology|October 31, 2018
PSMA PET applications in the prostate cancer journey: from diagnosis to theranosticsR S Eapen, T C Nzenza, D G Murphy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2023
Next generation radiotheranostics promoting precision medicineK L Pomykala, B A Hadaschik, O Sartor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 22, 2014
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)G Kong, M Thompson, M Collins, et al.
Anaesthesia|October 5, 2018
A pilot study of cardiopulmonary exercise testing and cardiac stress positron emission tomography before major non-cardiac surgeryM T Ferguson, M S Hofman, H Ismail, et al.
British Journal of Cancer|June 29, 2013
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapyC Y Cheah, M S Hofman, M Dickinson, et al.
Nature Communications|September 2, 2023
Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer modelsL H Porter, J J Zhu, N L Lister, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Best Practice & Research. Clinical Haematology|June 11, 2011
Imaging in follicular NHLM S Hofman, R J Hicks
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 13, 2011
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectableT W Barber, M S Hofman, B N J Thomson, et al.
World Journal of Urology|October 31, 2018
PSMA PET applications in the prostate cancer journey: from diagnosis to theranosticsR S Eapen, T C Nzenza, D G Murphy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2023
Next generation radiotheranostics promoting precision medicineK L Pomykala, B A Hadaschik, O Sartor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 22, 2014
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)G Kong, M Thompson, M Collins, et al.
Anaesthesia|October 5, 2018
A pilot study of cardiopulmonary exercise testing and cardiac stress positron emission tomography before major non-cardiac surgeryM T Ferguson, M S Hofman, H Ismail, et al.
British Journal of Cancer|June 29, 2013
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapyC Y Cheah, M S Hofman, M Dickinson, et al.
Nature Communications|September 2, 2023
Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer modelsL H Porter, J J Zhu, N L Lister, et al.
Pageof 1